JP2020535162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535162A5 JP2020535162A5 JP2020517419A JP2020517419A JP2020535162A5 JP 2020535162 A5 JP2020535162 A5 JP 2020535162A5 JP 2020517419 A JP2020517419 A JP 2020517419A JP 2020517419 A JP2020517419 A JP 2020517419A JP 2020535162 A5 JP2020535162 A5 JP 2020535162A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- pharmaceutical composition
- polymer matrix
- film according
- pharmaceutical film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims description 38
- 239000011159 matrix material Substances 0.000 claims description 30
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 13
- 239000000419 plant extract Substances 0.000 claims description 12
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 11
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 11
- 229960005139 epinephrine Drugs 0.000 claims description 11
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 9
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 9
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 229930015704 phenylpropanoid Natural products 0.000 claims description 8
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 4
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 claims description 4
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 4
- 239000005770 Eugenol Substances 0.000 claims description 4
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 4
- RGIBXDHONMXTLI-UHFFFAOYSA-N chavicol Chemical compound OC1=CC=C(CC=C)C=C1 RGIBXDHONMXTLI-UHFFFAOYSA-N 0.000 claims description 4
- 229930016911 cinnamic acid Natural products 0.000 claims description 4
- 235000013985 cinnamic acid Nutrition 0.000 claims description 4
- 229960002217 eugenol Drugs 0.000 claims description 4
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 4
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 claims description 4
- -1 labrazole Natural products 0.000 claims description 3
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 2
- IAZKGRRJAULWNS-UHFFFAOYSA-N Chavicol Natural products OC1=CC=C(CCC=C)C=C1 IAZKGRRJAULWNS-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 230000001851 biosynthetic effect Effects 0.000 claims description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 2
- 229930002886 farnesol Natural products 0.000 claims description 2
- 229940043259 farnesol Drugs 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 2
- 244000223014 Syzygium aromaticum Species 0.000 claims 4
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 45
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 244000061408 Eugenia caryophyllata Species 0.000 description 4
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010058151 Pulseless electrical activity Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229930014594 aporphine alkaloid Natural products 0.000 description 1
- 150000008441 aporphines Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 208000021816 ventricular bradycardia Diseases 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126682A JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/717,859 | 2017-09-27 | ||
| US15/717,859 US20180125977A1 (en) | 2016-05-05 | 2017-09-27 | Enhanced delivery epinephrine compositions |
| US15/791,249 | 2017-10-23 | ||
| US15/791,249 US12427121B2 (en) | 2016-05-05 | 2017-10-23 | Enhanced delivery epinephrine compositions |
| PCT/US2018/053042 WO2019067670A1 (en) | 2017-09-27 | 2018-09-27 | EPINEPHRINE AND ENHANCED DELIVERY COMPOSITIONS |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126682A Division JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A Division JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535162A JP2020535162A (ja) | 2020-12-03 |
| JP2020535162A5 true JP2020535162A5 (https=) | 2021-12-16 |
Family
ID=63858169
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517419A Pending JP2020535162A (ja) | 2017-09-27 | 2018-09-27 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2023126682A Pending JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A Pending JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126682A Pending JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A Pending JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3687510A1 (https=) |
| JP (3) | JP2020535162A (https=) |
| KR (1) | KR20200060748A (https=) |
| CN (1) | CN111465391A (https=) |
| BR (1) | BR112020005948A2 (https=) |
| CA (1) | CA3076816A1 (https=) |
| IL (2) | IL313551A (https=) |
| WO (1) | WO2019067670A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017192921A1 (en) | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| KR20220126286A (ko) * | 2019-11-01 | 2022-09-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 전구약물 조성물 및 치료 방법 |
| US11571468B2 (en) * | 2021-02-01 | 2023-02-07 | Matthias W. Rath | Micronutrient combination to reduce blood pressure |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| US20240016734A1 (en) * | 2022-06-14 | 2024-01-18 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| EP4302751A1 (en) * | 2022-07-07 | 2024-01-10 | LTS Lohmann Therapie-Systeme AG | Oral thin films with low water activity |
| CN118121542A (zh) * | 2023-03-31 | 2024-06-04 | 中国药科大学 | 鼻用药物组合物、其制备方法及应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US20030143195A1 (en) * | 2002-01-30 | 2003-07-31 | Pinsker Judy Senior | Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| US20040096569A1 (en) * | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| US20050266085A1 (en) * | 2004-05-28 | 2005-12-01 | Warner Kevin S | Gelled emulsion and microemulsion formulations for dermal drug delivery |
| US20070202163A1 (en) * | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| US20070293582A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| TW200816985A (en) * | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
| PE20091084A1 (es) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal |
| SG175160A1 (en) * | 2009-04-23 | 2011-11-28 | Londonpharma Ltd | Sublingual pharmaceutical composition comprising a neutral oil |
| ES2829386T3 (es) * | 2010-03-30 | 2021-05-31 | Phosphagenics Ltd | Parche de administración transdérmica |
| AU2012328448B2 (en) * | 2011-10-28 | 2017-02-02 | Sung-Yun Kwon | Dissolving solid solution perforator patch for migraine treatment |
| KR20150063567A (ko) * | 2012-10-11 | 2015-06-09 | 아이엑스 바이오파마 리미티드 | 고형 제형 |
| US20160051494A1 (en) * | 2014-08-21 | 2016-02-25 | Mylan, Inc. | Multi-dose medication kit for treating anaphylaxis |
| BR112018072467A2 (pt) * | 2016-05-05 | 2019-02-19 | Aquestive Therapeutics, Inc. | composições farmacêuticas com permeação aumentada |
| WO2017192921A1 (en) * | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
| EP3687508A1 (en) * | 2017-09-26 | 2020-08-05 | Aquestive Therapeutics, Inc. | Delivery pharmaceutical compositions including permeation enhancers |
-
2018
- 2018-09-27 KR KR1020207012106A patent/KR20200060748A/ko not_active Ceased
- 2018-09-27 CA CA3076816A patent/CA3076816A1/en active Pending
- 2018-09-27 EP EP18786593.6A patent/EP3687510A1/en active Pending
- 2018-09-27 BR BR112020005948-0A patent/BR112020005948A2/pt unknown
- 2018-09-27 CN CN201880063175.3A patent/CN111465391A/zh active Pending
- 2018-09-27 IL IL313551A patent/IL313551A/en unknown
- 2018-09-27 JP JP2020517419A patent/JP2020535162A/ja active Pending
- 2018-09-27 IL IL273485A patent/IL273485B2/en unknown
- 2018-09-27 WO PCT/US2018/053042 patent/WO2019067670A1/en not_active Ceased
-
2023
- 2023-08-03 JP JP2023126682A patent/JP2023159150A/ja active Pending
-
2025
- 2025-10-14 JP JP2025173124A patent/JP2026027254A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535162A5 (https=) | ||
| JP2020535176A5 (https=) | ||
| IL273485B2 (en) | Enhanced delivery epinephrine and prodrug compositions | |
| Arafa et al. | Propolis-based niosomes as oromuco-adhesive films: A randomized clinical trial of a therapeutic drug delivery platform for the treatment of oral recurrent aphthous ulcers | |
| RU2695217C2 (ru) | Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку | |
| RU2245715C2 (ru) | Композиция лака для ногтей | |
| RU2701513C2 (ru) | Фармацевтическая композиция, содержащая электрогидродинамически полученные волокна, композиция, имеющая улучшенное время удержания в месте применения | |
| EP3381448B1 (en) | Oral hemostatic and wound-protective film | |
| JP2019519488A5 (https=) | ||
| JP6491647B2 (ja) | キトサンペースト創傷手当て材 | |
| IL273479B1 (en) | Pharmaceutical compositions with enhanced permeation | |
| JP2019519487A5 (https=) | ||
| Hamman et al. | Use of natural gums and mucilages as pharmaceutical excipients | |
| Wadhwa et al. | Potential of plant mucilages in pharmaceuticals and therapy | |
| Gao et al. | A microparticle/hydrogel combination drug-delivery system for sustained release of retinoids | |
| CN110787150A (zh) | 一种含有氟比洛芬的皮肤外用制剂 | |
| CN102018686B (zh) | 含有丝裂霉素的膜剂及其制备方法 | |
| ME00828B (me) | Upotreba hitozana za lečenje inflamatornih oboljenja noktiju | |
| Kumar et al. | Natural excipients: A review | |
| JP2018177724A (ja) | 外用薬 | |
| CN102178644A (zh) | 马来酸噻吗洛尔眼用凝胶剂及其制备方法 | |
| KR101333892B1 (ko) | 항진균 조성물 | |
| CN114376964B (zh) | 一种葛根素纳米粒成膜水凝胶制剂及其制备方法 | |
| JP2018177725A (ja) | 外用薬 | |
| Milinković et al. | Hypromellose-based films and film-forming systems for topical application: current status and perspective in drug delivery |